Filing Details

Accession Number:
0000880771-16-000183
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-08-16 17:39:05
Reporting Period:
2016-08-12
Filing Date:
2016-08-16
Accepted Time:
2016-08-16 17:39:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
880771 Sciclone Pharmaceuticals Inc SCLN Pharmaceutical Preparations (2834) 943116852
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1576318 Hong Zhao 950 Tower Lane, Suite 900
Foster City CA 94404
Ceo, China Operations No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-08-12 12,500 $0.00 12,500 No 4 M Direct
Common Stock Disposition 2016-08-12 12,500 $10.41 0 No 4 S Direct
Common Stock Acquisiton 2016-08-12 25,000 $0.00 25,000 No 4 M Direct
Common Stock Disposition 2016-08-12 25,000 $10.41 0 No 4 S Direct
Common Stock Acquisiton 2016-08-12 3,000 $0.00 3,000 No 4 M Direct
Common Stock Disposition 2016-08-12 3,000 $10.41 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Acquisiton 2016-08-12 30,000 $0.00 30,000 $0.00
Common Stock Restricted Stock Unit Disposition 2016-08-12 12,500 $0.00 12,500 $0.00
Common Stock Restricted Stock Unit Disposition 2016-08-12 25,000 $0.00 25,000 $0.00
Common Stock Restricted Stock Unit Disposition 2016-08-12 3,000 $0.00 3,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
229,000 No 4 A Direct
216,500 No 4 M Direct
191,500 No 4 M Direct
188,500 No 4 M Direct
Footnotes
  1. Granted under the Issuer's 2015 Equity Incentive Plan.
  2. Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
  3. Each RSU will vest and be settled on August 15, 2017, subject to the reporting person's continued employment, but will terminate upon the occurrence of a change in control on or before March 31, 2017.
  4. Granted under the Issuer's 2005 Equity Incentive Plan.
  5. Provided Reporting Person remains employed by the Issuer, 25% of the restricted stock units will vest on each August 9, 2014, August 9, 2015, August 9, 2016, and August 9, 2017, unless the trading window is closed for the Reporting Person on such date, in which case the vesting date will be deferred until the next date that the trading window is open.
  6. Provided Reporting Person remains employed by the Issuer, 33.33% of the restricted stock units vested on January 4, 2016, 33.33% will vest on January 3,2017, and 33.34% will vest on January 2, 2017, unless the trading window is closed for the Reporting Person on such date, in which case the vesting date will be deferred until the next date that the trading window is open.
  7. Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.